Table 5.
Annual risk of grade 3/4 toxicities by regimen | Source | Anemia (%) | Febrile neutropenia (%) | Leukopenia (%) | Thrombocytopenia (%) | Infection (%) | Costs |
---|---|---|---|---|---|---|---|
Bendamustine + rituximab | [24] | 5.8402 | 0.0000 | 5.1316 | 9.3947 | 2.6842 | ¥ 26,614 |
Fludarabine + cyclophosphamide + rituximab | [25] | 6.8571 | 6.8571 | 0.0000 | 6.2857 | 2.8671 | ¥ 23,978 |
Ofatumumab | [10] | 10.8148 | 3.8518 | 0.0000 | 6.2222 | 10.0741 | ¥ 29,964 |
Ibrutinib | [10] | 2.1677 | 1.5871 | 1.0065 | 2.1677 | 7.7419 | ¥ 16,695 |